Norway's ArcticZymes Opens US Office; Expects Continued Growth in 2012 | GenomeWeb

By Ben Butkus

ArcticZymes, a Norwegian life science research tools firm specializing in cold-adapted and heat-labile enzymes for use in molecular biology and diagnostics, this week opened its first US office in the outskirts of Philadelphia.

The company is betting that its new digs will help it better serve its US customers, who are already responsible for most of its revenues, Jan Buch Andersen, managing director of ArcticZymes, told PCR Insider this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.